caa a22 4500 605478805 CHVBK 20210128100407.0 cr unu---uuuuu 210128e20150501xx s 000 0 eng 10.1007/s10741-014-9468-1 doi (NATIONALLICENCE)springer-10.1007/s10741-014-9468-1 Evidence of clinical efficacy of counterpulsation therapy methods [Elektronische Daten] [M. Capoccia, C. Bowles, J. Pepper, N. Banner, A. Simon] Although heart transplantation remains the ultimate treatment for end-stage heart failure, its epidemiological impact is limited by donor organ availability. Surgical and device-based approaches have been introduced with the aim of increasing systemic perfusion and in some circumstances promoting left ventricular recovery by inducing reverse remodelling. Innovative counterpulsation devices based on the established principle of the intra-aortic balloon pump have been developed, and of these, the CardioVad and the C-Pulse System have been introduced in clinical practice with convincing evidence of haemodynamic efficacy. The evolution from pulsatile to continuous-flow left ventricular assist devices has been associated with improved survival rates during the first 2years of support with the potential of matching heart transplantation outcomes. However, blood contact with the device remains a significant challenge despite the highly sophisticated technology currently available. Innovative extra-vascular counterpulsation devices have been shown to overcome the limitations of the intra-aortic balloon pump and rend the device suitable for prolonged support. Monitoring of the performance of these novel devices is essential, and carotid Doppler ultrasonography is of utility in assessing the haemodynamic performance of the devices in a clinical setting. Computational modelling has played a role in the simulation of these devices and should continue to assist with their optimisation and implementation in clinical practice. Springer Science+Business Media New York, 2014 Heart failure nationallicence IABP nationallicence LVAD nationallicence Counterpulsation nationallicence Capoccia M. Cardiothoracic Surgery, Royal Stoke University Hospital, Stoke-on-Trent, UK aut Bowles C. VAD Team, Harefield Hospital, London, UK aut Pepper J. Cardiothoracic Surgery, Royal Brompton Hospital, London, UK aut Banner N. Heart Failure Cardiology, Harefield Hospital, London, UK aut Simon A. Cardiothoracic and Transplant Surgery, Harefield Hospital, London, UK aut Heart Failure Reviews Springer US; http://www.springer-ny.com 20/3(2015-05-01), 323-335 1382-4147 20:3<323 2015 20 10741 https://doi.org/10.1007/s10741-014-9468-1 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10741-014-9468-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Capoccia M. Cardiothoracic Surgery, Royal Stoke University Hospital, Stoke-on-Trent, UK aut NATIONALLICENCE 700 1- Bowles C. VAD Team, Harefield Hospital, London, UK aut NATIONALLICENCE 700 1- Pepper J. Cardiothoracic Surgery, Royal Brompton Hospital, London, UK aut NATIONALLICENCE 700 1- Banner N. Heart Failure Cardiology, Harefield Hospital, London, UK aut NATIONALLICENCE 700 1- Simon A. Cardiothoracic and Transplant Surgery, Harefield Hospital, London, UK aut NATIONALLICENCE 773 0- Heart Failure Reviews Springer US; http://www.springer-ny.com 20/3(2015-05-01), 323-335 1382-4147 20:3<323 2015 20 10741